ESMO20 YO for YO: highlights on immune checkpoint blockade for triple-negative breast cancer

被引：0
|
作者：
Punie, K. [1 ,2 ]
Matikas, A. [3 ,4 ]
机构：
[1] Univ Hosp Leuven, Dept Gen Med Oncol, Herestr 49, B-3000 Leuven, Belgium
[2] Univ Hosp Leuven, Leuven Canc Inst, Multidisciplinary Breast Ctr, Leuven, Belgium
[3] Karolinska Inst, Oncol Pathol Dept, Stockholm, Sweden
[4] Karolinska Univ Hosp, Breast Ctr, Theme Canc, Stockholm, Sweden
来源：
ESMO OPEN | 2021年 / 6卷 / 01期
关键词：
D O I：
10.1016/j.esmoop.2020.100017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页数：2
相关论文
共 50 条
  • [31] ZDHHC9: a promising therapeutic target for triple-negative breast cancer through immune modulation and immune checkpoint blockade resistance
    Chao Xu
    Yongjie Xie
    Peng Xie
    Jianming Li
    Zhongsheng Tong
    Yanfang Yang
    Discover Oncology, 14
  • [32] Breaking Barriers: The Promise and Challenges of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer
    Said, Sawsan Sudqi
    Ibrahim, Wisam Nabeel
    BIOMEDICINES, 2024, 12 (02)
  • [33] Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?
    D'Abreo, Nina
    Adams, Sylvia
    NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (07) : 399 - 400
  • [34] Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives
    Yi, Huimei
    Li, Ying
    Tan, Yuan
    Fu, Shujun
    Tang, Faqing
    Deng, Xiyun
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [35] Phenotypes and cytokines of NK cells in triple-negative breast cancer resistant to checkpoint blockade immunotherapy
    Youlong Wang
    Yongluo Jiang
    Fadian Ding
    Jun Lu
    Tong Huang
    Guanqing Zhong
    Pengfei Zhu
    Yue Ma
    Jin Li
    Xinjia Wang
    Jiacai Lin
    Hongjun Zheng
    Weidong Wang
    Yiwei Xu
    Xiajie Lyu
    Yu Si Niu
    Xin Qi
    Jinjian Li
    Bocen Chen
    Tingting He
    Jiling Zeng
    Yifei Ma
    Breast Cancer Research, 27 (1)
  • [36] Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?
    Nina D’Abreo
    Sylvia Adams
    Nature Reviews Clinical Oncology, 2019, 16 : 399 - 400
  • [37] Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer
    Palakurthi, Bhavana
    Fross, Shaneann R.
    Guldner, Ian H.
    Aleksandrovic, Emilija
    Liu, Xiyu
    Martino, Anna K.
    Wang, Qingfei
    Neff, Ryan A.
    Golomb, Samantha M.
    Lewis, Cheryl
    Peng, Yan
    Howe, Erin N.
    Zhang, Siyuan
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [38] LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer
    Iván Pérez-Núñez
    Catalina Rozalén
    José Ángel Palomeque
    Irene Sangrador
    Mariona Dalmau
    Laura Comerma
    Anna Hernández-Prat
    David Casadevall
    Silvia Menendez
    Daniel Dan Liu
    Minhong Shen
    Jordi Berenguer
    Irene Rius Ruiz
    Raul Peña
    José Carlos Montañés
    M. Mar Albà
    Sarah Bonnin
    Julia Ponomarenko
    Roger R. Gomis
    Juan Miguel Cejalvo
    Sonia Servitja
    Diego M. Marzese
    Lluis Morey
    Leonie Voorwerk
    Joaquín Arribas
    Begoña Bermejo
    Marleen Kok
    Lajos Pusztai
    Yibin Kang
    Joan Albanell
    Toni Celià-Terrassa
    Nature Cancer, 2022, 3 : 355 - 370
  • [39] Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer
    Bhavana Palakurthi
    Shaneann R. Fross
    Ian H. Guldner
    Emilija Aleksandrovic
    Xiyu Liu
    Anna K. Martino
    Qingfei Wang
    Ryan A. Neff
    Samantha M. Golomb
    Cheryl Lewis
    Yan Peng
    Erin N. Howe
    Siyuan Zhang
    Nature Communications, 14
  • [40] LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer
    Perez-Nunez, Ivan
    Rozalen, Catalina
    Angel Palomeque, Jose
    Sangrador, Irene
    Dalmau, Mariona
    Comerma, Laura
    Hernandez-Prat, Anna
    Casadevall, David
    Menendez, Silvia
    Dan Liu, Daniel
    Shen, Minhong
    Berenguer, Jordi
    Ruiz, Irene Rius
    Pena, Raul
    Carlos Montanes, Jose
    Alba, M. Mar
    Bonnin, Sarah
    Ponomarenko, Julia
    Gomis, Roger R.
    Miguel Cejalvo, Juan
    Servitja, Sonia
    Marzese, Diego M.
    Morey, Lluis
    Voorwerk, Leonie
    Arribas, Joaquin
    Bermejo, Begona
    Kok, Marleen
    Pusztai, Lajos
    Kang, Yibin
    Albanell, Joan
    Celia-Terrassa, Toni
    NATURE CANCER, 2022, 3 (03) : 355 - +
12345